Please assess the completion status of the following clinical trial:

Trial Title: Double Stimulation Followed by a Fresh Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Poor prognosis patients according to the POSEIDON group 3 \& 4 (based on AMH)~* AMH \<1.2~* age \<40 years old~* BMI \>18 and \<35 kg/m2~* Body weight \>50kg (in women \<36 years old body weight \>60kg)~Exclusion Criteria:~* Maternal age \> 40 years~* History of untreated autoimmune, endocrine or metabolic disorders~* Previous ovarian cystectomy or oophorectomy~* Body weight \<50kg (and body weight \<60kg in women \<36 years old)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Double Stimulation (Elonva+rFSH) in luteal /follicular phase (Type: EXPERIMENTAL): A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp \& Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.~A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.~This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)
- Conventional Stimulation (Elonva+rFSH) in follicular phase (Type: ACTIVE_COMPARATOR): A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG

Based on this trial design, predict the completion outcome and termination type (if applicable).